Fotemustine in patients with advanced gastric cancer, a phase II trial from the EORTC-GITCCG (European Organization for Research and Treatment of Cancer, Gastrointestinal Tract Cancer Cooperative Group)

P Rougier; C van Pottelsberghe; T Kok; B Paillot; T Wagener; J De Greve; M C Fabri; B Gerard; M Van Glabbeke; H Bleiberg

doi:10.1016/0959-8049(96)00088-3

Fotemustine in patients with advanced gastric cancer, a phase II trial from the EORTC-GITCCG (European Organization for Research and Treatment of Cancer, Gastrointestinal Tract Cancer Cooperative Group)

Eur J Cancer. 1996 Jul;32A(8):1432-3. doi: 10.1016/0959-8049(96)00088-3.

Authors

P Rougier¹, C van Pottelsberghe, T Kok, B Paillot, T Wagener, J De Greve, M C Fabri, B Gerard, M Van Glabbeke, H Bleiberg

Affiliation

¹ Gastrointestinal Unit, Gustave Roussy Institute, Villejuif, France.

PMID: 8869111
DOI: 10.1016/0959-8049(96)00088-3

Abstract

Fotemustine activity was evaluated in 26 patients, mostly pretreated, with advanced gastric cancer. Its main toxicity was haematological with grade 3-4 neutropenia in 32% and grade 3-4 thrombocytopenia in 50% of the patients, complicated by 2 toxicity-related deaths due to haemorrhage. No complete or partial responses were observed in the 26 eligible patients and median survival was only 11 weeks. Fotemustine therefore has no activity in advanced gastric cancer.

Publication types

Clinical Trial
Clinical Trial, Phase II

MeSH terms

Adult
Aged
Antineoplastic Agents / adverse effects
Antineoplastic Agents / therapeutic use*
Female
Hematologic Diseases / chemically induced
Humans
Male
Middle Aged
Nitrosourea Compounds / adverse effects
Nitrosourea Compounds / therapeutic use*
Organophosphorus Compounds / adverse effects
Organophosphorus Compounds / therapeutic use*
Stomach Neoplasms / drug therapy*
Treatment Outcome

Substances

Antineoplastic Agents
Nitrosourea Compounds
Organophosphorus Compounds
fotemustine